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Abstract
Background: Calcineurin (CaN) is an important serine-threonine phosphatase (PP2B), which
plays a crucial role in calcium-calmodulin mediated signal transduction events. Calcineurin has been
implicated in pathogenesis of various diseases cardiac hypertrophy, diabetic neuropathy and
Alzheimer's, however its role in neoplasia remains unclear.
Results: In view of this we evaluated the calcineurin activity in serum and biopsy samples collected
from women diagnosed with invasive squamous cell carcinoma of cervix. A significant reduction
was observed in the calcineurin activity in cancer cervix patients compared to the control group.
However the calcineurin activity remained unaltered in the cervical scrapes obtained from patients
diagnosed with low-grade squamous intra epithelial lesions (LSIL). Interestingly the downregulation
of calcineurin activity in squamous cell carcinomas was not accompanied by any significant change
in DNA-binding affinity of the transcriptional factor NFAT (Nuclear Factor of Activated T-cells).
All the squamous cell carcinoma samples used in the present study were positive for high-risk
human papillomavirus (HPV) types.
Conclusion:  The present study demonstrates the downregulation of calcineurin activity in
squamous cell carcinoma of cervix with high risk HPV infection. We conclude that perturbations
in calcineurin-mediated pathway may be involved in development of cervical neoplasia.
Introduction
Cervical cancer is one of the most prevalent neoplastic dis-
eases affecting women world wide, especially in the devel-
oping countries [1,2]. In India, cervical neoplasia is not
only the most common malignancy but also a major
cause of death among middle-aged women particularly in
the rural areas [3,4]. It is well established now that infec-
tion with human papilloma virus (HPV) is a major etio-
logical risk factor for development of cervical cancer,
however other host/environmental factors contribute to
the progression of the disease [5-7]. Infection with HPV
can modulate the host factors involved in signaling cas-
cades and deregulation of signaling pathways is a hall-
mark of cancer. An important feature of the signal
transduction pathway is reversible serine/threonine phos-
phorylation of proteins and any aberrant activity in the
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kinases or phosphatases can disturb the phosphorylation/
dephosphorylation cycle leading to uncontrolled prolifer-
ation. Therefore, identification of key-signaling molecules
(kinases and phosphatases) responsible for neoplastic
development can have potential clinical relevance allow-
ing for diagnosis, early detection and intervention.
There is a plethora of information existing on the involve-
ment of various kinases such MAPK [8], PI3K [9], JNK
[10], cdk4 [11,12], cdc2 [13], Her2 [14], p38 [15] etc. in
cervical carcinoma cells. While the phosphatases such as
cdc25A/C and PTEN have been shown to be associated
with cervical cancer [12,16,17], the existing information
falls short on the involvement of serine/threonine protein
phosphatase family members viz., PP1, PP2A, PP2B (cal-
cineurin) and PP2C. There is only one report, which dem-
onstrates downregulation of protein phosphatase 1,
regulatory subunit in cervical cancer cells [18]. In view of
the limited information available on involvement of ser-
ine/threonine phosphatase, an attempt was made in the
present study to investigate if there is any association
between calcineurin and cervical neoplasia.
Calcineurin is the only serine/threonine phosphatase
whose activity is modulated by both calcium and calmod-
ulin and it is a crucial mediator of the calcium mediated
signal transduction pathways. Calcineurin is a het-
erodimeric protein consisting of a catalytic subunit (cal-
cineurin A), with an active metal binding centre, and a
regulatory subunit (calcineurin B), which binds to cal-
cium [19]. One of the major functions of calcineurin is T-
cell activation by dephosphorylation of the transcrip-
tional factor NFAT (Nuclear Factor of Activated T-cells)
[20]. Calcineurin is involved in a wide variety of biologi-
cal responses including neuronal and muscle develop-
ment, neurite outgrowth, morphogenesis of vertebrate
heart valves, memory development, behavioral response
etc [21-26]. In addition, calcineurin has also been impli-
cated in pathogenesis of diseases such as cardiac hypertro-
phy, Alzheimer's, schizophrenia, diabetic nephropathy
and Down's syndrome [27-32]. Calcineurin plays a role in
apoptosis via inducing the cytochrome c/caspase depend-
ent pathway and by dephosphorylating Bad, a proapototic
member of Bcl-2 family [33,34]. Recent studies have also
demonstrated the involvement of calcineurin in the cell
cycle by regulation of the cdk4 (cyclin dependent kinase
4), a G0/G1 checkpoint element [35]. The immunosup-
pressant cyclosporin A (CsA), which specifically inhibits
calcineurin activity, has proved to be a useful tool in
understanding the role of calcineurin in various cellular
processes. CsA has been shown to exert an antiprolifera-
tive effect not only in T cell but also in a wide variety of
cells including lymphomas, keratinocytes, fibroblasts and
smooth muscle cells indicating that calcineurin activity is
important for cell cycle progression [36]. In contrast to the
antiproliferative action of CsA in cell culture system, it has
been shown that treatment with CsA in kidney transplant
recipients is associated with increased incidence of renal
cancer [37,38]. However it is still unclear if the genesis of
cancer in CsA administered persons is due to direct inhi-
bition of calcineurin-mediated pathways or its other indi-
rect effects. This warrants a study on involvement of
calcineurin in cancer progression and therefore the
present study was undertaken to ascertain the importance
of calcineurin in cervical neoplasia.
Materials and methods
Specimen collection
For the present study patient's consent was taken and the
study was approved by the institutional bioethical com-
mittee. Cervical biopsy samples were collected (N = 45)
from women diagnosed with invasive cervical cancer. The
biopsy samples collected from patients were immediately
snap frozen in liquid nitrogen. Cervical tissue specimens
(N = 30) collected from women undergoing hysterectomy
for non-neoplastic conditions formed the control group.
Blood samples (3 ml) were collected in plain bottles
[without anticoagulant] from both the normal and cancer
patients. Blood was allowed to clot and serum was sepa-
rated by centrifugation at 3000 rpm for 10 min at room
temperature. The serum samples were stored at -20°C till
further use.
Cervical scrapes were also collected using Ayer's spatula
from women attending the cervical screening outpatient
clinic (N = 30). Four of these women were found to have
low-grade intraepithelial lesion (LSIL) and the rest with
chronic inflammation only on cytology. The cervical
scrape was collected in chilled phosphate buffer saline
(pH 7.2) and the cells were collected by centrifugation at
13000 rpm for 10 min at 4°C. The supernatant was dis-
carded and the cells were immediately frozen in liquid
nitrogen till further use.
Sample preparation
Tissues (100 mg) and cervical scrapes were homogenized
in 500 µl or 250 µl of buffer A respectively, containing 25
mM HEPES (pH 7.2), 150 mM NaCl, 1% NP-40, 10 mM
MgCl2, 10% glycerol, 10 µg/ml PMSF and 10 µg/ml apro-
tinin for 3 min. The homogenates were cleared of the
debris by centrifugation at 13,000 rpm for 10 min at 4°C.
The supernatants were aliquoted and stored at -70°C till
further use.
Assay for calcineurin
An aliquot of the homogenized sample (100 µl) was
passed through sephadex G-25 column (Amersham Phar-
macia) to eliminate the free phosphate and further used
for calcineurin activity. The protein estimation was done
using the BCA Kit [Pierce company] as per theCancer Cell International 2005, 5:7 http://www.cancerci.com/content/5/1/7
Page 3 of 8
(page number not for citation purposes)
manufacturers protocol. Calcineurin activity was assayed
in a total volume of 50 µl containing 25 µl of 2X assay
buffer (200 mM NaCl, 100 mM Tris [pH 7.5], 12 mM
MgCl2, 1 mM CaCl2) and 5 µl of the cell/tissue homoge-
nate. The samples were incubated with 2X-assay buffer for
10 min at 30°C. The total volume was adjusted to 50 µl
by the addition of water. Reactions were initiated by add-
ing RII phosphopeptide [5 µM] and incubated for a fur-
ther period of 10 min at 30°C. Reactions were terminated
by addition of 100 µl of Malachite green reagent (3 vol. of
0.045% Malachite green and 1 vol. of 4.2% ammonium
molybdate in 4N HCl). The color was allowed to develop
for 30 min and the absorbance read at 660 nm. The cal-
cineurin activity was calculated as nmoles of inorganic
phosphate released/min/mg total protein in case of tis-
sues and for serum samples as nmoles of inorganic phos-
phate released/min/dl of serum.
Determination of calmodulin and calcineurin contents in 
tissue lysates
The calmodulin and calcineurin contents were deter-
mined by competitive ELISA methods as described earlier
[39]. The calcineurin antibody against the catalytic subu-
nit A was used in this study.
Electrophoretic mobility shift assay for NFATc-DNA 
binding
Electrophoretic mobility shift assay (EMSA) was per-
formed using oligonucleotide with consensus binding site
for NFATc (5'CGCCCAAAGAAAATTTGTTTCATA3').
Briefly, biopsy tissues were homogenized and the nuclear
pellet was collected by centrifugation (600 × g: 10 min,
4°C). The nuclear lysates (100 µg) were prepared and
incubated in 25 µl of reaction mixture containing polydI/
dC, 10X binding buffer (50 µM ZnCl 2,0.25 mM DTT, 20
mM Tris [pH 7.5], 60 mM KCl, 1 mM MgCl2 0.1 mM
EDTA, 10% glycerol) and the labeled oligo for 30 min at
room temperature. The reactions were terminated using
25 µl of the loading dye and loaded onto a 7% gel retar-
dation assay gel. The run was done at 250 V for 3 hrs at
4°C. At the end of the run, the gel was removed, dried and
exposed in a phosphoimager overnight at room
temperature.
HPV-testing and Typing
The DNA isolated from the squamous cell carcinoma sam-
ples were tested for presence of HPV by a PCR based
reverse line blot assay as described earlier (40)
Statistical analysis
Comparisons between the normal and the cancer samples
were done using the Student's t-test for paired data.
Results
1. Calcineurin activity in serum and cervical tissue (normal 
vs squamous cell carcinoma)
Calcineurin activity was assayed in both sera and tissue
lysate by measuring the dephosphorylation of RII peptide,
a specific substrate of calcineurin. The biopsy samples col-
lected from the cancer patients were classified as moder-
ately differentiated large cell non-keratinising squamous
cell carcinomas of the cervix. We observed a significant
reduction in the calcineurin activity both in the cervical
tissues (p = 0.0001) and sera (p = 0.0037) of patients with
invasive cervical cancer in comparison to the control
group (Fig. 1). It has to be noted that we have calculated
the calcineurin activity in serum as nmoles of phosphate
released/min/deciliter. However if we consider the total
protein content per deciliter of serum for each sample and
accordingly calculate the calcineurin activity per milli-
gram of serum protein, the calcineurin activity in serum
will be much lower than that of tissue. Since the interna-
tional standard for representing the units for enzyme
activity for serum/plasma is represented in units per
deciliter/litre the same has been represented in Fig. 1a.
2. Calmodulin and calcineurin A content in cervical tissues 
(normal vs squamous cell carcinoma)
The calmodulin and calcineurin contents were also ana-
lyzed in the biopsies, to evaluate if the decrease in the cal-
cineurin activity could be correlated with their respective
contents. The content for both calcineurin A subunit and
calmodulin was measured using competitive ELISA
method in the tissue samples. There was no change in the
level of calcineurin A between the control and the cancer
samples (Fig. 2). Interestingly, there was a significant
increase in the calmodulin level in cervical carcinoma
(Fig. 3).
3. Calcineurin activity in Low-grade squamous cell 
intraepithelial lesions
To correlate the decrease in calcineurin activity with the
early dysplastic changes, we collected cervical scrapes
from thirty women attending the outpatient department
in the hospital. Of these four were diagnosed as Low-
grade squamous intraepithelial lesions (LSIL) by cytology
and the rest were cytologically normal but with chronic
inflammation. We didn't observe any significant change
in the calcineurin activity between the LSIL and the con-
trols in the cervical scrapes (Fig. 4).
4. NFAT activity
In view of our observation on downregulation of cal-
cineurin activity in cervical carcinoma, we wanted to
investigate if there is any alteration in the DNA-binding
activity of NFAT, one of the major substrates of cal-
cineurin. We analyzed the nuclear extracts from 5 squa-
mous cell carcinoma and 5 controls by incubating it withCancer Cell International 2005, 5:7 http://www.cancerci.com/content/5/1/7
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the radiolabelled oligonucleotide probes specific for
NFAT binding. Interestingly we didn't find any significant
change in the DNA binding affinity of NFAT between can-
cer and the control samples (Fig. 5).
5. HPV typing and testing
A PCR-based reverse line blot assay (40) was used to check
the presence of HPV types in the squamous cell carcino-
mas. We could detect oncogenic HPV-types (16,18,31,45
etc) in all of the cervical cancer but none in the control
samples, however we could not correlate the presence of
HPV-types with any variation in calcineurin activity (data
not shown).
Discussion
The present study shows downregulation of calcineurin
activity in invasive cervical cancer. High calcineurin activ-
ity can lead to apoptosis [33], thereby indicating that the
downregulation in calcineurin activity can help in cellular
survival thereby promoting neoplastic progression. In a
previous study [41] a decrease in calcineurin activity in
MCF-7 cells following retinoic acid treatment has been
linked to downregulation in the expression level of cata-
lytic subunit (A) of calcineurin, however in our study we
didn't find any alterations in the level of calcineurin A.
The basis for the decrease in calcineurin activity observed
in cervical neoplasia in absence of a change in Calcineurin
Calcineurin activity in serum (a) and biopsy samples (b) of control and cervical cancer patients diagnosed with squamous cell  carcinoma (SCC) Figure 1
Calcineurin activity in serum (a) and biopsy samples (b) of control and cervical cancer patients diagnosed with squamous cell 
carcinoma (SCC). The calcineurin activity is significantly reduced in serum samples [1a, p = 0.0001] and in tissue lysates [1b, p 
= 0.0037] obtained from cancer patients compared to the normal group. The calcineurin activity was calculated as nmoles of 
inorganic phosphate released per mg protein of tissues or per deciliter of serum.Cancer Cell International 2005, 5:7 http://www.cancerci.com/content/5/1/7
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A content needs to be identified and we speculate that a
change in redox state of the cancer cell due to oxidative
stress contributes to the alteration in the activity of cal-
cineurin without altering its content. Calcineurin by vir-
tue of its Fe2+-Zn2+ binuclear center in its active site is
oxidized to Fe3+-Zn2+ by superoxide and hydrogen perox-
ide ions [42]. Superoxide dismutase (SOD), a free radical
scavenging enzyme, protects calcineurin from inactivation
by superoxide and hydrogen peroxide ions [43,44]. Low
levels of the antioxidants such as glutathione, Vitamin E
and C as well as superoxide dismutase have been reported
to be lower in cervical cancer [45,46], which in turn can
modulate the calcineurin activity. Interestingly the lower
SOD in circulation reported in cervical cancer [46] may
have a role in downregulation of the serum calcineurin
activity. There is clearly strong evidence on the involve-
ment of reactive oxygen species (ROS) in cervical cancer
[47] and it can most likely alter the calcineurin activity
atleast in the tissues without affecting its expression. This
argument is also supported by an observation that activity
of creatine kinase B, a ROS sensitive protein, is downreg-
ulated in cervical cancer [48]. Another possible mecha-
nism of inhibition in calcineurin activity is through
upregulation of naturally occurring endogenous inhibi-
tors of calcineurin such as calcipressin 1/DSCR1 and for-
skolin binding protein [31,49]. The role of these negative
regulators of calcineurin in cervical cancer is not known.
However it is interesting to note that oxidative stress mod-
ulates the calcipressin expression and phosphorylation
status [50], which in turn can affect the calcineurin
activity.
Total calcineurin content in normal and cervical cancer tissue  lysates [SCC] Figure 2
Total calcineurin content in normal and cervical cancer tissue 
lysates [SCC]. The calcineurin content was assayed by using 
antibody specific to calcineurin [Sigma monoclonal anti-
CaNα , 1:7500 dilution using a sandwich ELISA method.
Total calmodulin content in normal and cervical cancer tissue  lysates (SCC) were determined by using antibody specific to  calmodulin Figure 3
Total calmodulin content in normal and cervical cancer tissue 
lysates (SCC) were determined by using antibody specific to 
calmodulin. Note a significant increase [p = 0.0263] in cal-
modulin content in cancer patients.
Calcineurin activity as determined in the cervical scrapes  obtained from control (N = 25) and those diagnosed with  low-grade intraepithelial squamous lesion (LSIL) or CIN1 Figure 4
Calcineurin activity as determined in the cervical scrapes 
obtained from control (N = 25) and those diagnosed with 
low-grade intraepithelial squamous lesion (LSIL) or CIN1. 
Note, no significant change in calcineurin activity in control 
and LSIL group.Cancer Cell International 2005, 5:7 http://www.cancerci.com/content/5/1/7
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The natural history of invasive cervical cancer involves
sequential progression of persistent HPV infection to
reversible LSIL (CIN1) and then to high-grade intraepithe-
lial lesions (HGIL/CIN2). In the presence of other precip-
itating factors HSIL is a direct precursor of invasive cancer
[51]. To evaluate if calcineurin activity is also altered in
early precancerous lesions we examined the calcineurin
activity in cervical scrapes collected from LSIL cases. Inter-
estingly, there was no significant alteration in the cal-
cineurin activity in the early precursor lesions (LSIL)
compared to the control group. None of the samples col-
lected in this study were of HSIL. It has to be however
noted that unlike the biopsy specimens of squamous cell
carcinoma consisting mostly of the clonally derived
malignant cells, the cervical scrapes collected is a mixed
population of both the normal and the dysplastic cells. It
is possible that the overwhelming number of normal cells
in the cervical scrapes diagnosed as LSIL resulted in no sig-
nificant difference in the calcineurin activity between the
control and LSIL group. On the other hand more samples
of LSIL and HSIL precursor lesions have to be analyzed
before we rule out the possibility of calcineurin involve-
ment in the early stages of cervical cancer progression.
Nonetheless, the significant decline in calcineurin activity
in invasive squamous cell carcinoma is suggestive of its
role in cervical neoplasia.
NFAT-DNA-binding activity in normal and cervical cancer nuclear extracts Figure 5
NFAT-DNA-binding activity in normal and cervical cancer nuclear extracts. Briefly 100 µg of nuclear extracts was incubated 
with 32P-labelled NFATc oligonucleotide and Electrophoretic mobility shift assay was performed as described in Material and 
methods. Lane one contains free probe without nuclear extract and lane 2 contains 100-fold excess of unlabelleled NFAT oli-
gonucleotide as a specific competitor. Specific NFAT- DNA complexes are indicated by arrow.Cancer Cell International 2005, 5:7 http://www.cancerci.com/content/5/1/7
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The regulation of gene expression in response to calcium
stimuli is one of the most explored functions of cal-
cineurin. Importantly, the critical target of calcineurin is
the NFAT family of transcription factors. Calcineurin
dephosphorylates NFAT allowing translocation of this
protein into the nucleus [19]. Studies conducted on
preadipocyte cell line (3T3-L1) have demonstrated that
constitutive expression of NFATc1 can induce cellular
transformation providing a direct evidence for the onco-
genic potential of the NFATc1 transcription factor [52].
Further, NFAT has also been linked to tumor metastasis
[53]. In view of the above evidence, it was of interest to
investigate the activation of NFAT in cervical cancer. There
was no major difference in DNA binding affinity of NFAT
from nuclear extracts obtained from cancer and the con-
trol samples. The results on the unaltered DNA binding
activity of NFAT seem at odds in view of the reduced cal-
cineurin activity in the cervical neoplasia. However, it is
possible that regulation of NFAT by calcineurin is cell type
specific and is not affected by calcineurin in cervical cells.
Another possibility could be, that calcineurin is known to
exist in different isoforms (α ,β , ↓ ) and it is probable that
the isoforms existing in cervix has a different substrate
specificity. Besides NFAT, calcineurin can also modulate
the phosphorylation status of other key regulatory
proteins such as Bad, IkB and NFkB, which in turn can
promote neoplasia by disturbing the balance existing
between cell death and proliferation [30,54]. Already the
NFkB mediated pathway is known to be upregulated in
cervical cancer progression [55]. Decrease in calcineurin
activity could lead to cellular survival by deregulating
these major players thereby maintaining the malignant
phenotype of cervical neoplasia.
Conclusion
In conclusion, our pilot study is indicative of a possible
role of calcineurin-mediated pathway in pathogenesis of
cervical neoplasia. While NFAT is a major target of cal-
cineurin, our study rules out the involvement of this tran-
scriptional factor indicating presence of a NFAT
independent calcineurin pathway atleast in cervical can-
cer. The present investigation has opened up new avenues
to evaluate further the role of calcineurin in cervical cancer
progression.
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